drugset
drugset / Trial / NCT02151344

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

NCT02151344 ↗

Phase 1 Completed 100 enrolled National Institute of Allergy and Infectious Diseases (NIAID)
Non-randomizedParallel-groupOpen-labelPrevention

Summary

H7N9 viruses have caused a recent outbreak of severe illness in humans in China. The purpose of this study is to evaluate the safety and immune response of an H7N9 A/Anhui/13 ca influenza virus vaccine followed by an inactivated subvirion H7N9 vaccine at varying intervals.

Timeline

Start
2014-05
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject H7N9 A/Anhui/13 ca influenza virus vaccine Vaccine 1e+07 unknown Intranasal
Subject H7N9 pIIV Vaccine 30 ug Other

Indications

swine influenza